Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease

• Published in: Medicine (Baltimore) Vol. 98; no. 38; p. e17208
• Main Authors: Martinez-Fierro, Margarita L., Garza-Veloz, Idalia, Rocha-Pizaña, Maria R., Cardenas-Vargas, Edith, Cid-Baez, Miguel A., Trejo-Vazquez, Fabiola, Flores-Morales, Virginia, Villela-Ramirez, Gabriela A., Delgado-Enciso, Ivan, Rodriguez-Sanchez, Iram P., Ortiz-Castro, Yolanda
• Format: Journal Article
• Language: English
• Published: United States the Author(s). Published by Wolters Kluwer Health, Inc 01-09-2019; Wolters Kluwer Health
• Subjects: Adalimumab - therapeutic use; Adult; Aged; Anti-Inflammatory Agents - therapeutic use; Azathioprine - therapeutic use; Becaplermin - blood; Biomarkers - blood; Case-Control Studies; Chemokine CXCL10 - blood; Chemokines - blood; Cytokines - blood; Female; Granulocyte Colony-Stimulating Factor - blood; Humans; Inflammatory Bowel Diseases - blood; Inflammatory Bowel Diseases - drug therapy; Intercellular Signaling Peptides and Proteins - blood; Interleukin-6 - blood; Male; Mesalamine - therapeutic use; Middle Aged; Observational Study; Receptors, Interleukin-1 - blood
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000017208

Ulcerative colitis (UC) and Crohn disease (CD) are the most common forms of inflammatory bowel disease (IBD). Because these subtypes of IBD are characterized by periods of activity and remission, an understanding of the modulation of biochemical markers with the clinical features of IBD or its treatment, may be useful for determining the correct treatment protocol.This study aimed to evaluate the serum levels of 27 protein biomarkers to determine their association with IBD, correlation with clinical findings of disease, and modulation according to the pharmacologic therapy.A case-control study was carried out in Zacatecas, Mexico. The 27 protein profiles of serum from 53 participants (23 UC, 11 CD, and 19 controls) were evaluated using the Pro Human Cytokine 27-Plex immunoassay (Bio-Rad).Considering the controls as a reference, the group with IBD endoscopic activity showed higher serum levels of granulocyte colony-stimulating factor (G-CSF), interleukin 1 receptor antagonist (IL-1Ra), and platelet-derived growth factor BB (PDGF-BB) (P < .05). Interferon-induced protein 10 (IP-10) was associated with extraintestinal symptoms of disease (P = .041). Both PDGF-BB and interleukin 6 (IL-6) showed the strongest correlations with clinical features of IBD. Levels of IL-6, IL-7, and monocyte chemoattractant protein 1 were higher with 5-aminosalicylic acid (5-ASA) + Azathioprine therapy than controls (P < .05). Combined therapy with 5-ASA + Adalimumab led to the strongest changes in marker modulation: IL-4, IL-5, IL-15, and PDGF-BB, were upregulated (P < .05).Elevated serum levels of G-CSF, IL-1Ra, and PDGF-BB were associated with IBD endoscopic activity, and of IP-10 with extraintestinal manifestations of IBD. Combined therapy of 5-ASA + Adalimumab produced significant upregulation of IL-4, IL-5, IL-15, and PDGF-BB. This information may be useful for deciding on the course of pharmacologic therapy for patients with IBD and for generating new therapy alternatives to improve the outcome of patients with IBD.